Drug intelligence / Profile preview

zoster vaccine, live

Development stage: Approved
Lead developer: Merck
Modality: Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

Zoster vaccine, live is a live attenuated virus vaccine used to prevent herpes zoster (shingles) in individuals 50 years of age and older. It contains a weakened form of the varicella-zoster virus to stimulate an immune response that protects against reactivation of the virus as shingles. The primary indication is prevention of herpes zoster; it is not indicated for treatment of active shingles or postherpetic neuralgia. Zostavax was developed by Merck & Co., and was first approved in 2006 but has since been discontinued in the United States[1][3][5][8].

Brand names: Zostavax
Other names: varicella zoster vaccine (live/attenuated)

Targets

Varicella-zoster virus antigens

Beyond the preview

Go deeper on zoster vaccine, live.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zoster vaccine, live.

Explore the full profile